Tenor Capital Management’s enGene Therapeutics Warrants ENGNW Stock Holding History

Tenor Capital Management’s Portfolio ENGNW Stock Details ENGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-55,243	Closed	-$140K	–	550
2026 Q1	$140K	Hold	55,243	–	–	﹤0.01%	335
2025 Q4	$164K	Hold	55,243	–	–	﹤0.01%	307
2025 Q3	$39.2K	Hold	55,243	–	–	﹤0.01%	318
2025 Q2	$45.3K	Hold	55,243	–	–	﹤0.01%	280
2025 Q1	$33.2K	Hold	55,243	–	–	﹤0.01%	216
2024 Q4	$46.6K	Hold	55,243	–	–	﹤0.01%	188
2024 Q3	$116K	Hold	55,243	–	–	﹤0.01%	162
2024 Q2	$65.7K	Sell	55,243 -9,757	-15%	-$31.2K	﹤0.01%	169
2024 Q1	$338K	Sell	65,000 -51,666	-44%	-$157K	0.01%	177
2023 Q4	$99.2K	Buy	+116,666	New	+$89.7K	﹤0.01%	178

Other funds holding ENGNW

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return

Tenor Capital Management's ENGNW Position: Q2 2026 in Review

Tenor Capital Management sold out of enGene Therapeutics Warrants (ENGNW) in Q2 2026, closing a stake of 55,243 shares — an estimated $140K sold.

Tenor Capital Management first reported a position in ENGNW in Q4 2023 and held it in 10 quarters. The position peaked at $338K in Q1 2024. 11 funds tracked by Wall St. Rank hold ENGNW as of Q2 2026.

Tenor Capital Management reported no remaining enGene Therapeutics Warrants position as of Q2 2026 after selling out during the quarter.
Tenor Capital Management sold 55,243 enGene Therapeutics Warrants shares in Q2 2026, an estimated $140K.
Tenor Capital Management first reported a position in enGene Therapeutics Warrants in Q4 2023 and held it in 10 quarters.
Tenor Capital Management's enGene Therapeutics Warrants position peaked at $338K in Q1 2024.
11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q2 2026.

Based on Tenor Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.